Agalsidase-Beta Therapy for Advanced Fabry Disease

A Randomized Trial

  1. Maryam Banikazemi, MD;
  2. Jan Bultas, MD, PhD;
  3. Stephen Waldek, MB, BCh;
  4. William R. Wilcox, MD, PhD;
  5. Chester B. Whitley, PhD, MD;
  6. Marie McDonald, MD;
  7. Richard Finkel, MD;
  8. Seymour Packman, MD;
  9. Daniel G. Bichet, MD;
  10. David G. Warnock, MD;
  11. Robert J. Desnick, PhD, MD; and
  12. for the Fabry Disease Clinical Trial Study Group*
  1. From the Mount Sinai School of Medicine of New York University, New York, New York; University Hospital, Prague, Czech Republic; Hope Hospital and Salford Royal Hospital National Health Service Trust, Manchester, United Kingdom; Medical Genetics Institute and Cedars-Sinai Medical Center, Los Angeles, California; University of Minnesota, Minneapolis, Minnesota; Duke University Medical Center, Durham, North Carolina; The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; University of California, San Francisco, San Francisco, California; University of Montréal, Montréal, Québec, Canada; and University of Alabama at Birmingham, Birmingham, Alabama.
     
    Next Section

    Abstract

    Background: Fabry disease (α-galactosidase A deficiency) is a rare, X-linked lysosomal storage disorder that can cause early death from renal, cardiac, and cerebrovascular involvement.

    Objective: To see whether agalsidase beta delays the onset of a composite clinical outcome of renal, cardiovascular, and cerebrovascular events and death in patients with advanced Fabry disease.

    Design: Randomized (2:1 treatment-to-placebo randomization), double-blind, placebo-controlled trial.

    Setting: 41 referral centers in 9 countries.

    Patients: 82 adults with mild to moderate kidney disease; 74 of whom were protocol-adherent.

    Intervention: Intravenous infusion of agalsidase beta (1 mg per kg of body weight) or placebo every 2 weeks for up to 35 months (median, 18.5 months).

    Measurements: The primary end point was the time to first clinical event (renal, cardiac, or cerebrovascular event or death). Six patients withdrew before reaching an end point: 3 to receive commercial therapy and 3 due to positive or inconclusive serum IgE or skin test results. Three patients assigned to agalsidase beta elected to transition to open-label treatment before reaching an end point.

    Results: Thirteen (42%) of the 31 patients in the placebo group and 14 (27%) of the 51 patients in the agalsidase-beta group experienced clinical events. Primary intention-to-treat analysis that adjusted for an imbalance in baseline proteinuria showed that, compared with placebo, agalsidase beta delayed the time to first clinical event (hazard ratio, 0.47 [95% CI, 0.21 to 1.03]; P = 0.06). Secondary analyses of protocol-adherent patients showed similar results (hazard ratio, 0.39 [CI, 0.16 to 0.93]; P = 0.034). Ancillary subgroup analyses found larger treatment effects in patients with baseline estimated glomerular filtration rates greater than 55 mL/min per 1.73 m2 (hazard ratio, 0.19 [CI, 0.05 to 0.82]; P = 0.025) compared with 55 mL/min per 1.73 m2 or less (hazard ratio, 0.85 [CI, 0.32 to 2.3]; P = 0.75) (formal test for interaction, P = 0.09). Most treatment-related adverse events were mild or moderate infusion-associated reactions, reported by 55% of patients in the agalsidase-beta group and 23% of patients in the placebo group.

    Limitations: The study sample was small. Only one third of the patients experienced clinical events, and some patients withdrew before experiencing any event.

    Conclusions: Agalsidase-beta therapy slowed progression to the composite clinical outcome of renal, cardiac, and cerebrovascular complications and death compared with placebo in patients with advanced Fabry disease. Therapeutic intervention before irreversible organ damage may provide greater clinical benefit.

    *For a list of members of the Fabry Disease Clinical Trial Study Group, see the Appendix.

    ClinicalTrials.gov identifier: NCT00074984.

    Click here for related information on Fabry disease.

    Editors' Notes

    Context

    • Fabry disease is an X-linked storage disorder characterized by deficient lysosomal enzyme activity and excessive deposition of glycosphingolipids in vascular endothelial cells.

    Contribution

    • In this double-blind multicenter trial, 82 adults with kidney dysfunction from Fabry disease were randomly assigned to infusions of enzyme replacement with agalsidase beta or placebo every 2 weeks for up to 35 months. Agalsidase beta reduced the frequency of and delayed the time to clinical events (composite outcome of renal, cardiac, and cerebrovascular events and death) and caused infusion reactions more often than placebo.

    Caution

    • Most clinical events in the small trial were worsening kidney function.

    Implication

    • Agalsidase beta may slow disease progression in patients with advanced Fabry disease.

    —The Editors

    Fabry disease is a rare, X-linked lysosomal storage disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A (α-Gal A). The resultant progressive accumulation of its substrates (globotriaosylceramide and related glycosphingolipids) has profound clinical consequences, particularly in the vascular endothelial cells of the kidney and heart (1, 2). Early manifestations typically include debilitating chronic acroparesthesias, episodic excruciating pain “crises,” hypohidrosis, and abdominal pain and diarrhea. Subsequent kidney failure, heart disease, and strokes lead to early death, typically at age 40 to 50 years (1, 3–5). Heterozygous females can have serious disease manifestations due to nonrandom X-chromosomal inactivation (6–8). Late-onset variants have been described (9–11).

    Two clinical trials in patients with Fabry disease demonstrated that enzyme replacement with agalsidase beta (recombinant human α-Gal A, Fabrazyme, Genzyme Corp., Cambridge, Massachusetts) (12–16) clears globotriaosylceramide from the capillary endothelia of the kidney, heart, and skin—the major sites of pathology in Fabry disease. On the basis of the results of these trials, agalsidase beta was approved in Europe in 2001 and in the United States by the U.S. Food and Drug Administration (FDA), under its accelerated approval program, in 2003. Since approval was based on a surrogate marker, the FDA required an additional trial to demonstrate clinical benefit. Thus, our objective was to evaluate the effect of agalsidase beta on disease progression by a time-to-event analysis of renal, cerebrovascular, and cardiac events or death in patients with advanced Fabry disease in a placebo-controlled trial.

    Previous SectionNext Section

    Methods

    Design Overview

    This multicenter, randomized, double-blind, placebo-controlled study began in February 2001 and ended in January 2004. We used a 2:1 treatment-to-placebo randomization ratio to give more patients access to treatment (Figure 1). Because Fabry disease is multisystemic, we chose a composite primary end point. Natural history data related to clinical events in Fabry disease are limited; thus, we planned 2 interim analyses (which did not require unblinding the study) to evaluate whether trial duration and patient numbers were adequate. Institutional review boards at all sites approved the protocol. All patients gave written informed consent at trial entry and were informed in April 2003 that the commercial drug had become available in the United States.

    Figure 1.
    View larger version:
    Figure 1. Study flow diagram.

    Setting and Participants

    Physicians who were experienced in treating Fabry disease were contacted at 41 university or research hospitals in 9 countries in North America and Europe. Patients were recruited through mailings, advertisements, Web site postings, physician-to-physician and physician-to-patient information letters, and patient meetings. Eligible patients were at least 16 years of age with clinical evidence of Fabry disease; α-Gal A activity less than 1.5 nmol/h per mL of plasma (normal mean, 8.1 nmol/h per mL of plasma [SD, 3.2] [n = 218]) or less than 4 nmol/h per mg of leukocyte protein (normal mean, 97.5 nmol/h per mg of leukocyte protein [SD, 16.4] [n = 46]); no previous enzyme replacement therapy; and the following evidence of kidney disease: 2 consecutive serum creatinine measurements of 106 µmol/L or greater (≥1.2 mg/dL) and less than 265 µmol/L (<3.0 mg/dL) or, if the serum creatinine measurement was less than 106 µmol/L (<1.2 mg/dL), an estimated creatinine clearance less than 1.33 mL/s (<80 mL/min) (Cockcroft–Gault equation). We excluded patients who were undergoing dialysis or were scheduled for kidney transplantation; those with documented transient ischemic attacks, ischemic stroke, unstable angina, or myocardial infarction within 3 months of trial entry; and those with confounding conditions or other clinically significant comorbid conditions.

    Randomization and Interventions

    Randomization codes were computer-generated and were maintained centrally at a secure location. The 2:1 randomization scheme was blocked (block size of 3, which was not revealed to investigators) at each site. Study materials were packaged identically, and sponsor staff, investigators, and patients were blinded to treatment allocation. Every 2 weeks, patients received either agalsidase beta (1 mg/kg of body weight) or placebo (phosphate-buffered mannitol) administered intravenously at an initial rate of 0.25 mg/min, which was increased after the eighth infusion as tolerated to decrease the infusion time to a minimum of 90 minutes. All patients were pretreated with acetaminophen or ibuprofen and some patients with an antihistamine to minimize infusion-associated reactions (defined as adverse events on the treatment day considered to be treatment-related) (13).

    Outcome and Measurements

    The following measures were performed or obtained at baseline and at the final study visit or time of study withdrawal: serum creatinine level, proteinuria (ratio of urinary protein to urinary creatinine [in mg/dL]), ratio of urinary albumin to urinary creatinine (in mg/dL), 12-lead electrocardiography, echocardiography, neurologic examination, head magnetic resonance imaging, Brief Pain Inventory, exercise tolerance, plasma globotriaosylceramide level, Fabry symptom assessment, physical examination, blood chemistries, urinalysis, IgG antibody titers to agalsidase beta, and optional skin biopsy. Every 4 weeks, serum creatinine levels were measured, and all baseline measures were repeated every 12 weeks, except for echocardiography, head magnetic resonance imaging, and exercise tolerance, which were repeated every 24 weeks. The estimated glomerular filtration rate (GFR) was determined by using the 4-variable Modification of Diet in Renal Disease formula (17).

    The primary end point was the time to first clinical event (renal, cardiac, or cerebrovascular event or death) in the placebo and agalsidase-beta groups. We defined a renal event as a 33% increase in serum creatinine level from baseline (2 consecutive values) or end-stage kidney disease requiring long-term dialysis or transplantation. We defined a cardiac event as myocardial infarction; new symptomatic arrhythmia requiring antiarrhythmic medication, pacemaker, direct current cardioversion, or defibrillator implantation; unstable angina defined by national practice guidelines (18) and accompanied by electrocardiographic changes resulting in hospitalization; or worsening congestive heart failure requiring hospitalization. We defined a cerebrovascular event as a stroke or transient ischemic attack documented by a physician. Patients were allowed to transition to open-label agalsidase beta after an independent adjudication board confirmed that a primary end point event had occurred.

    Safety monitoring included physician evaluation and documentation of adverse events. At each study visit, investigators asked patients an open-ended question about their health status. They also reviewed the results of all physical examinations, electrocardiographies, and laboratory assessments and reported any clinically significant symptom or abnormality as an adverse event. They assessed all adverse events for seriousness, severity, and relatedness to treatment. An independent data monitoring committee, which was authorized to recommend study termination on the basis of the methods of O'Brien and Fleming (19), periodically reviewed safety data.

    Serum was collected at baseline and every 4 weeks thereafter for detection and measurement of IgG antibody titers to agalsidase beta at the Genzyme Immunology Laboratory, Framingham, Massachusetts, as described previously (15). If an investigator suspected that an infusion-associated reaction was IgE-mediated, serum IgE tests or skin tests to agalsidase beta were performed. According to the protocol, we withdrew patients with positive test results from the study.

    Follow-up Procedures

    On trial completion, patients were eligible to enroll in an 18-month, open-label extension study. We contacted patients for safety follow-up if they withdrew or chose not to continue in the extension study.

    Statistical Analysis

    We chose a final sample size of 80 patients to provide 80% power for detecting a treatment effect on the basis of log-rank testing by using a 10% drop-out rate; a 14-month enrollment period and 18 months of follow-up; type I error of 0.05 (2-sided); and expected event rates over 2 years of 40% and 10% for patients in the placebo and agalsidase-beta groups, respectively, as predicted by an estimated 20% to 30% decline per year in estimated GFR (3, 20). To ensure that the proposed trial duration and sample size were adequate, the data monitoring committee conducted blinded interim analyses of event rates at 12 months and 18 months, and the study duration was increased from 24 months to 29 months and then to 35 months. Because the trial remained blinded and no hypothesis testing was performed, the type I error rate was not adjusted for the primary end point (21).

    Efficacy analyses, which were performed by using SAS, version 8.2 (SAS Institute Inc., Cary, North Carolina), included only data that were obtained while patients received double-blind treatment. To evaluate the treatment effect in the time-to-event analyses, Kaplan–Meier methods were used for unadjusted analyses and the Cox proportional-hazards model was used for proteinuria-adjusted analyses (22, 23). Because of the small sample size, the protocol specified that any imbalance in important prognostic factors after randomization could be adjusted by using the Cox proportional-hazards model (22, 23). More patients in the agalsidase-beta group had elevated baseline proteinuria, which was significantly associated with time to any clinical end point and with time to renal end point. In addition, adding a term for proteinuria to the Cox proportional-hazards model with a term for treatment resulted in a 23% change in the hazard ratio for treatment. Hence, we applied a change in estimate criterion (24) and determined that baseline proteinuria was the most important potential confounder. Adjusted analyses were performed using Cox proportional-hazards models with a term for baseline proteinuria. Because the distribution of baseline proteinuria was skewed, adjusted analyses also were performed using fourth-root transformations of proteinuria values to invoke a normal distribution (25). The proportional-hazards assumptions were tested by assessing the treatment-by-time interaction and the proteinuria-by-time interaction. Both interactions were nonsignificant.

    Hazard ratios, 95% CIs, and P values were calculated for the treatment effect for the composite outcome and for renal events with and without proteinuria adjustment. Odds ratios for cardiovascular and cerebrovascular events were calculated by Fisher exact test with StatXact, version 3 (Cytel Software Corp., Cambridge, Massachusetts) (26). We conducted the primary end point analyses in the intention-to-treat population and, as secondary analyses, in a prespecified per-protocol population.

    We performed ancillary analyses that were not specified by the protocol in the intention-to-treat population. These included time-to-event analyses and formal tests for treatment interaction in subgroups stratified by median baseline proteinuria and by median baseline serum creatinine level and median baseline estimated GFR with adjustment for baseline proteinuria. Proteinuria, serum creatinine levels, and estimated GFR were examined over the course of the study and compared by treatment group by using mixed-model analyses. Linear mixed-effects models were fit with fixed effects for treatment group, time, and treatment-by-time interactions, as well as random intercepts and slopes, for each patient over time.

    The investigators asked patients about adverse events and monitored for adverse events during double-blind and open-label treatment. Adverse events were coded using the World Health Organization Adverse Reaction Terminology (WHO-ART) (27). Frequency, severity, and causality data that directly compared events among patients taking agalsidase beta or placebo were assessed during the double-blind treatment period.

    Role of the Funding Sources

    The Genzyme Corporation and the National Center for Research Resources, a component of the National Institutes of Health, supported the trial. The Genzyme project team participated in the design of the trial in collaboration with the study investigators and the senior author, with input from the FDA (28). A contract research organization performed site monitoring and source data verification. Genzyme, in conjunction with the investigators, performed the data management and statistical analyses. Genzyme provided funding for writing services and reviewed the manuscript for accuracy but had no formative role in data interpretation, writing or revising the manuscript, or the decision to submit the paper for publication.

    Previous SectionNext Section

    Results

    Of the 252 patients screened, 82 eligible patients (intention-to-treat population) were treated at 26 sites in 6 countries. Fifty-one patients were randomly assigned to the agalsidase-beta group and 31 patients were randomly assigned to the placebo group (Figure 1). The baseline characteristics of patients in the 2 groups were similar, except for proteinuria (Table 1). Of note, 4 (proteinuria, estimated GFR, hemoglobin level, and serum albumin level) of 15 (serum creatinine level, estimated creatinine clearance, angiotensin-converting enzyme inhibitor use, sex, urinary albumin–urinary creatinine ratio, history of hypertension, race or ethnicity, age, plasma globotriaosylceramide level, body mass index, and weight) baseline variables were associated with time to clinical event. Of these 4 variables, proteinuria was most strongly associated with any clinical event (hazard ratio, 1.3 [95% CI, 1.1 to 1.6]; P = 0.005) and any renal event (hazard ratio, 1.4 [CI, 1.2 to 1.8]; P < 0.001).

    View this table:
    Table 1. Baseline Characteristics*

    From the first infusion to the final blinded visit, patients received treatment for up to 35 months. Mean and median treatment durations were 18.4 months (SD, 8.8) and 18.5 months, respectively. At the end of the study, 71 patients were still enrolled, 8 withdrew, and 3 died. Six withdrawals occurred before an end point event: 2 patients in the agalsidase-beta group and 1 patient in the placebo group withdrew to obtain commercial therapy, which became available in the United States during the trial, and 3 patients in the agalsidase-beta group withdrew due to positive or inconclusive skin test results or positive IgE test results. Two withdrawals, 1 from each group, were voluntary and occurred after an end point event. In addition, 3 patients in the agalsidase-beta group who had not met the primary end point elected to transition to open-label treatment after 13 to 17 months. We excluded them from further efficacy analyses upon transition but included them in safety analyses. The deaths of 2 patients, 1 from each group, occurred after a primary end point. The death of 1 patient in the agalsidase-beta group was the primary end point (see Adverse Events section).

    Eight patients were excluded in the per-protocol population before unblinding because of major protocol violations: 4 patients in the agalsidase-beta group who missed 22% to 87% of infusions, 1 patient in the placebo group who missed 22% of infusions, 1 patient in the placebo group who did not meet the required clinical inclusion criteria, and 2 patients in the placebo group who received a wrong treatment. Thus, the per-protocol population had 74 patients: 47 patients in the agalsidase-beta group and 27 patients in the placebo group. Of the excluded patients, 1 patient in the agalsidase-beta group had a cardiac event and 1 patient in the placebo group had a renal event.

    Primary End Point and Protocol-Specified Secondary Analyses

    Thirteen (42%) of 31 patients in the placebo and 14 (27%) of 51 patients in the agalsidase-beta group had clinical events (Table 2). The intention-to-treat analysis of time to first clinical event that adjusted for baseline imbalance in proteinuria favored agalsidase beta (hazard ratio, 0.47 [CI, 0.21 to 1.03]; P = 0.06) (Figure 2, top). We observed a similar effect of agalsidase beta when the time-to-event analyses were repeated using fourth-root transformations of proteinuria to normalize the skewed distribution (hazard ratio, 0.49 [CI, 0.22 to 1.1]; P = 0.07).

    View this table:
    Table 2. Primary End Point Events in the Intention-to-Treat Population*
    Figure 2.
    View larger version:
    Figure 2. Analyses of time to first clinical outcome.

    Dashed lines show Kaplan–Meier estimates of time to any clinical event (composite outcome). Solid lines show curves with adjustment for baseline proteinuria (urine protein–creatinine ratio), derived from a Cox regression analysis with baseline proteinuria added as a covariate to the regression equation (22, 23). Top. The time-to-event analyses for the composite end point for both treatment groups in the intention-to-treat population are shown. The unadjusted treatment-related hazard ratio associated with agalsidase beta was 0.57 (95% CI, 27.0 to 1.22; P = 0.14). With adjustment for baseline proteinuria, the hazard ratio was 0.47 (CI, 0.21 to 1.03; P = 0.06). Bottom. The time-to-event analyses for the composite end point for both treatment groups in the per-protocol population are shown. The unadjusted treatment-related hazard ratio associated with agalsidase beta was 0.54 (CI, 0.25 to 1.19; P = 0.12). With adjustment for baseline proteinuria, the hazard ratio was 0.39 (CI, 0.16 to 0.93; P = 0.034).

    Most clinical events were renal; however, hazard ratios and odds ratios for renal, cardiac, and cerebrovascular events separately were also consistent with a treatment effect (Table 2). Secondary analyses of protocol-adherent patients that adjusted for baseline proteinuria demonstrated a more pronounced treatment effect compared with placebo (hazard ratio, 0.39 [CI, 0.16 to 0.93]; P = 0.034) (Figure 2, bottom).

    Ancillary Analyses

    Figure 3 shows the treatment effects evaluated in subgroups stratified by the median value for each of 3 baseline kidney function measures. Patients with baseline estimated GFRs greater than 55 mL/min per 1.73 m2 (hazard ratio, 0.19 [CI, 0.05 to 0.82]; P = 0.025) had a stronger treatment effect than patients with GFRs of 55 mL/min per 1.73 m2 or less (hazard ratio, 0.85 [CI, 0.32 to 2.3]; P = 0.75) (formal test for treatment interaction using models that adjusted for baseline proteinuria, P = 0.09). Patients with baseline serum creatinine levels of 132.6 µmol/L or less (≤1.5 mg/dL) had greater treatment effects (hazard ratio, 0.25 [CI, 0.07 to 0.90]; P = 0.034) than those with baseline serum creatinine levels greater than 132.6 µmol/L (>1.5 mg/dL) (hazard ratio, 0.80 [CI, 0.29 to 2.21]; P = 0.66) (formal test for treatment interaction, P = 0.16). We observed a less pronounced difference in patients with baseline proteinuria of 1 or less (hazard ratio, 0.41 [CI, 0.13 to 1.3]; P = 0.13) versus patients with proteinuria greater than 1 (hazard ratio, 0.67 [CI, 0.24 to 1.9]; P = 0.44) (formal test for treatment interaction, P = 0.54).

    Figure 3.
    View larger version:
    Figure 3. Hazard ratios for the primary end point stratified by median baseline serum creatinine level, estimated glomerular filtration rate (eGFR), and proteinuria.

    Proteinuria denotes the urine protein–creatinine ratio. The P values for formal tests for treatment interaction were as follows: baseline serum creatinine level, P = 0.16; baseline eGFR, P = 0.09; and baseline proteinuria, P = 0.54.

    Mean serum creatinine level, estimated GFR, and proteinuria did not change between baseline and final assessment in either treatment group. Longitudinal analyses showed nonsignificant decreases in proteinuria and nonsignificant increases in inverse serum creatinine level and estimated GFR over time for the agalsidase-beta group compared with the placebo group (Appendix Figure).

    Appendix Figure.
    View larger version:
    Appendix Figure. Longitudinal analysis of proteinuria in both groups.Graphic

    Data are shown as increases or decreases from baseline proteinuria (urinary protein–urinary creatinine ratio) for the placebo group (solid line) and the agalsidase-beta group (dashed line). A mixed model with fixed effects for treatment group, time, and treatment-by-time interactions, as well as random intercepts and slopes, for each patient over time was fit. The overall P value for treatment effect is 0.32.

    Adverse Events

    Overall, 99% of trial participants experienced adverse events, such as rhinitis, coughing, or headache, during the trial. Most events occurred in similar frequencies in both groups and seemed to be unrelated to drug treatment (Appendix Table). During double-blind treatment, 61% of patients in the agalsidase-beta group and 32% of patients in the placebo group reported treatment-related adverse events (Table 3). Most treatment-related events were mild or moderate infusion-associated reactions (most commonly rigors and fever), which occurred in 55% of patients in the agalsidase-beta group and 23% of patients in the placebo group. Most infusion-associated reactions occurred during the first 6 months of treatment.

    View this table:
    Appendix Table. Adverse Events That Occurred without Regard to Causality in at Least 10% of Patients in the Agalsidase-Beta GroupGraphic
    View this table:
    Table 3. Summary of Adverse Events

    Of 56 serious adverse events reported for 30 patients, only 3 events were considered to be treatment-related. One patient in the agalsidase-beta group experienced severe hypotension and subsequently had a positive serum IgE test result. We withdrew this patient from the trial. One patient in the agalsidase-beta group developed urticaria and throat congestion, and another patient developed urticaria, rigors, and fever during infusions. Both patients subsequently had positive skin test results. We withdrew 1 patient from the trial, and the other patient continued participation as an institutional review board–approved protocol exception. Both withdrawn patients were subsequently rechallenged and continued receiving the commercial drug. No patient experienced anaphylaxis.

    Three patients died during the study. All had clinically significant histories of cardiovascular disease, cerebrovascular disease, or both. The patient in the agalsidase-beta group whose death was a primary end point died of multiple pulmonary emboli. The patient had massive lymphedema and had habitually used methamphetamine. The other 2 patients died secondary to their primary end points: 1 patient in the agalsidase-beta group died of sudden cardiac arrest and 1 patient in the placebo group died of cardiac arrest 1 week after a stroke. The investigators did not consider any death to be related to treatment.

    The investigators detected IgG antibodies in 43 (68%) of the 63 patients who received agalsidase beta at any time during the trial. Of the 55 men who received agalsidase beta, 14 (26%) remained seronegative. Titers were not available for 1 man after his transition to open-label therapy. Of the 8 women who received agalsidase beta, 5 (63%) remained seronegative. One seropositive man and all 3 seropositive women tolerized. Mean infusion time decreased during the study to almost half of the initial time in both treatment groups.

    Previous SectionNext Section

    Discussion

    This randomized, double-blind, placebo-controlled trial showed that agalsidase-beta therapy reduced the likelihood of any clinical event (composite outcome) in patients with advanced Fabry disease, indicating a slower progression of severe manifestations. Among the renal, cardiac, and cerebrovascular end points monitored in the study, deteriorating kidney function was the most frequent, which is not surprising because mild to moderate kidney disease was required for trial participation. As in earlier studies, agalsidase beta was tolerated reasonably well; transient mild or moderate infusion-associated reactions occurred in 55% of the treated patients and declined in frequency over time (12, 13, 15). The results of our trial support and extend the findings of smaller studies and case reports describing the effects of agalsidase-beta therapy, 1 mg/kg every 2 weeks (15, 29–38). These studies, identified by a MEDLINE search of clinical trials on Fabry disease published between 2000 and October 2006, report improvements in cardiac function (30, 31, 35), gastrointestinal symptoms (36, 38), and heat tolerance and physical activity (33), as well as stabilization of kidney function (15), reduction of pain (30, 33), and reduction of neuropathic abnormalities (32).

    In Fabry disease, glycosphingolipid deposition begins before birth (39) and is cumulative. Thus, early intervention with enzyme replacement therapy would be more beneficial than later intervention, when substrate accumulation may have caused irreversible organ damage. More than a decade of experience with enzyme replacement therapy for a related lysosomal storage disease, type 1 Gaucher disease, has clearly demonstrated that early intervention can prevent progressive disease manifestations (40). The patients with Fabry disease who participated in our trial had an average of 45 years of glycosphingolipid accumulation, resulting in significant kidney dysfunction. We observed greater treatment effects in patients with less severe kidney dysfunction at baseline (Figure 3), although formal tests for interaction were nonsignificant, perhaps due to the small sample size. This is consistent with the results of a recent open-label, single-center study of 26 patients who received agalsidase beta (1 mg/kg every 2 weeks) for a mean of 23 months. Of the 9 patients who experienced clinical events (death, dialysis initiation, myocardial infarction, coronary artery bypass grafting, cardiac pacemaker implantation, or atrial fibrillation), all had impaired kidney function at study entry (38).

    In our trial, proteinuria emerged as a predictor of clinical outcome. Proteinuria is a well-known risk factor for the progression of kidney disease and cardiovascular illness (41–44), and it was recently implicated as a risk factor for progression of kidney involvement in Fabry disease (15). We did not observe a treatment effect with respect to proteinuria, although longitudinal analyses showed a non–statistically significant decrease in proteinuria in patients in the agalsidase-beta group compared with those in the placebo group. These findings suggest that proteinuria should be monitored in patients with Fabry disease. Treatment with antiproteinuria drugs, such as angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers, should be evaluated, because these drugs have been effective in other diseases and chronic conditions that are associated with proteinuria (45, 46). We did not design our trial to evaluate the effects of renoprotective drugs because their potential benefits had not been established when the trial began enrollment. Few patients were taking these drugs at baseline, and the duration of therapy and the specific drugs and dosages prescribed varied considerably. Further studies to evaluate the effect of antiproteinuria drugs on clinical outcome in the setting of enzyme replacement therapy may demonstrate their importance as an adjunctive therapy for Fabry disease.

    The major limitation of our trial was the small sample size because of the rarity of Fabry disease and the narrow window of disease severity necessary to quantify clinical benefit within a reasonable time frame. Only one third of the participants experienced clinical events. Six patients withdrew from the double-blind trial before experiencing any outcome event: 3 to obtain commercial therapy and 3 due to positive or inconclusive skin test results or positive IgE test results. Eight patients had major protocol violations, including 5 patients who missed 22% to 87% of their infusions. The effect of such protocol deviations may be negligible in clinical efficacy trials that involve hundreds of participants in each treatment group, but the effect can be substantial when patient numbers are small, as discussed in recent guidelines prepared by the European Medicines Agency for clinical trials in small study populations (47). In particular, nonsystematic errors introduced by protocol violations, such as missed treatments, can lead to bias toward treatment failure.

    In conclusion, our placebo-controlled trial indicates that agalsidase beta, 1 mg/kg every 2 weeks, can slow the progression of the serious, life-threatening complications of Fabry disease, even in patients who already have overt kidney dysfunction. Our results also support the rationale for early treatment and the need to evaluate the potential benefit of renoprotective drugs in Fabry disease.

    Previous SectionNext Section

    Appendix: Fabry Disease Clinical Trial Study GroupGraphic

     
    Next Section

    Investigators

    Maryam Banikazemi, MD (New York, New York); John A. Barranger, MD, PhD (Pittsburgh, Pennsylvania); Daniel G. Bichet, MD (Montréal, Canada); David Bodensteiner, MD (Kansas City, Kansas); Jan Bultas, MD (Prague, Czech Republic); David Bushinsky, MD (Rochester, New York); Joel Charrow, MD (Chicago, Illinois); Robert J. Desnick, PhD, MD (New York, New York); Christine M. Eng, MD (Houston, Texas); Richard W. Erbe, MD (Buffalo, New York); Paul Fernhoff, MD (Atlanta, Georgia); Richard Finkel, MD (Philadelphia, Pennsylvania); Robert M. Greenstein, MD (Farmington, Connecticut); János Grubits, MD (Sopron, Hungary); Robert J. Hopkin, MD (Cincinnati, Ohio); Marie McDonald, MD (Durham, North Carolina); Seymour Packman, MD (San Francisco, California); C. Ronald Scott, MD (Seattle, Washington); Katherine B. Sims, MD (Boston, Massachusetts); Anna Tylki-Szymanska, MD (Warsaw, Poland); Stephen Waldek, MB, BCh (Manchester, United Kingdom); David G. Warnock, MD (Birmingham, Alabama); Neal Weinreb, MD (Coral Springs, Florida); Michael L. West, MD (Halifax, Nova Scotia, Canada); William R. Wilcox, MD, PhD (Los Angeles, California); Chester B. Whitley, PhD, MD (Minneapolis, Minnesota); and Philip Wyatt, MD (Toronto, Ontario, Canada).

    Previous Section
     

    Genzyme Personnel

    Rekha Abichandani, MD; Amy Burke; Rebecca Cintron, MD; Laura Fitzgerald; Mark Goldberg, MD; Eilleen Horgan; Donna Mackey; Richard Moscicki, MD; Fanny O'Brien, PhD; Sue Richards, PhD; P.K. Tandon, PhD; Crystal C.-C. Sung, PhD; and Karen Welch.

    Previous SectionNext Section

    Article and Author Information

    • Disclaimer: The views expressed herein are those of the authors and do not necessarily reflect those of the National Center for Research Resources or the National Institutes of Health.

    • Acknowledgments: The authors thank the patients, nurses, and hospital staff who participated in the study, as well as Lisa Underhill for writing assistance.

    • Grant Support: By the National Center for Research Resources of the National Institutes of Health grants to the Mount Sinai School of Medicine (grant 5 M01 RR00071); Cedars-Sinai Medical Center (grant 5 M01 RR00425); University of Minnesota (grant 5 M01 RR00400); The Children's Hospital of Philadelphia (grant 5 M01 RR00240); University of California, San Francisco (grant 5 M01 RR01271); and University of Alabama at Birmingham (grant 5 M01 RR00032). Additional support came from the National Institutes of Health Merit Award 5 R37 DK34045 (Dr. Desnick) and from the Genzyme Corporation.

    • Potential Financial Conflicts of Interest: Consultancies: J. Bultas (Genzyme Corp.), W.R. Wilcox (Genzyme Corp.), S. Packman (Genzyme Corp.), D.G. Bichet (Genzyme Corp.), D.G. Warnock (Genzyme Corp.), R.J. Desnick (Genzyme Corp., Amicus Therapeutics); Honoraria: M. Banikazemi (Genzyme Corp.), S. Waldek (Genzyme Corp.), W.R. Wilcox (Genzyme Corp.), C.B. Whitley (Genzyme Corp.), M. McDonald (Genzyme Corp.), D.G. Bichet (Genzyme Corp.), D.G. Warnock (Genzyme Corp.); Stock ownership or options (other than mutual funds): M. McDonald (Genzyme Corp.), R.J. Desnick (Amicus Therapeutics); Grants received: S. Waldek (Genzyme Corp., Amicus Therapeutics), W.R. Wilcox (Genzyme Corp.), C.B. Whitley (BioMarin, Genzyme Corp.), M. McDonald (Genzyme Corp.), R. Finkel (Genzyme Corp.), S. Packman (Genzyme Corp.), D.G. Bichet (Genzyme Corp.), D.G. Warnock (Genzyme Corp.), R.J. Desnick (Genzyme Corp.); Grants pending: D.G. Warnock (Genzyme Corp.); Patents received: R.J. Desnick (Mount Sinai School of Medicine to Genzyme Corp. for Fabrazyme); Royalties: R.J. Desnick (Genzyme Corp.).

    • Requests for Single Reprints: Robert J. Desnick, PhD, MD, Department of Human Genetics, Mount Sinai School of Medicine, Fifth Avenue at 100th Street, Box 1498, New York, NY 10029-6574; e-mail, admin.desnick{at}mssm.edu.

    • Current Author Addresses: Dr. Banikazemi: New York University, 403 East 34th Street, 2nd Floor, New York, NY 10016.

    • Dr. Bultas: Second Department of Medicine, Charles University, U Nemocnice 2, 128 08 Prague 2, Czech Republic.

    • Dr. Waldek: Department of Lysosomal Storage Diseases, Hope Hospital, Salford Royal Hospital Trust, Manchester M6 8HD, United Kingdom.

    • Dr. Wilcox: Division of Medical Genetics, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.

    • Dr. Whitley: Gene Therapy Center, Department of Pediatrics, Institute of Human Genetics, 420 Delaware Street SE, MMC 446, Minneapolis, MN 55455.

    • Dr. McDonald: Division of Medical Genetics, Duke University Medical Center, Box 3528, Durham, NC 27710.

    • Dr. Finkel: Division of Neurology, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104.

    • Dr. Packman: Division of Medical Genetics, Department of Pediatrics, University of California, San Francisco, 533 Parnassus Avenue, Room U-585K, San Francisco, CA 94143-0748.

    • Dr. Bichet: Université de Montréal, Hôpital du Sacré-Coeur de Montréal, 5400, boul. Gouin Ouest, Montréal H4J 1C5, Québec, Canada.

    • Dr. Warnock: Division of Nephrology, University of Alabama, 1530 3rd Avenue South, THT 647, Birmingham, AL 35233.

    • Dr. Desnick: Department of Human Genetics, Mount Sinai School of Medicine, Fifth Avenue at 100th Street, Box 1498, New York, NY 10029-6574.

    • Author Contributions: Conception and design: M. Banikazemi, S. Packman, D.G. Bichet, R.J. Desnick.

    • Analysis and interpretation of the data: W.R. Wilcox, C.B. Whitley, R. Finkel, S. Packman, D.G. Bichet, D.G. Warnock, R.J. Desnick.

    • Drafting of the article: M. Banikazemi, S. Packman, D.G. Warnock, R.J. Desnick.

    • Critical revision of the article for important intellectual content: M. Banikazemi, J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, R. Finkel, S. Packman, D.G. Bichet, D.G. Warnock, R.J. Desnick.

    • Final approval of the article: M. Banikazemi, J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, M. McDonald, R. Finkel, S. Packman, D.G. Bichet, D.G. Warnock, R.J. Desnick.

    • Provision of study materials or patients: J. Bultas, S. Waldek, W.R. Wilcox, C.B. Whitley, M. McDonald, R. Finkel, S. Packman, D.G. Bichet, D.G. Warnock.

    • Administrative, technical, or logistic support: C.B. Whitley.

    • Collection and assembly of data: W.R. Wilcox, C.B. Whitley, S. Packman, D.G. Bichet.

    Previous Section
     

    References

    1. 1.↵
      1. DesnickRJ,
      2. IoannouYA,
      3. EngCM
      Alpha-galactosidase A deficiency: Fabry disease.Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein BThe Metabolic and Molecular Bases of Inherited Disease. 8th ed.3New YorkMcGraw-Hill20013733-74
      Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. vol 3. New York: McGraw-Hill; 2001:3733-74.
    2. 2.↵
      1. DesnickRJ,
      2. BradyR,
      3. BarrangerJ,
      4. CollinsAJ,
      5. GermainDP,
      6. GoldmanM
      et al.Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.Ann Intern Med2003138338-46pmid:12585833
      Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338-46. [PMID: 12585833]
      Abstract/FREE Full Text
    3. 3.↵
      1. BrantonMH,
      2. SchiffmannR,
      3. SabnisSG,
      4. MurrayGJ,
      5. QuirkJM,
      6. AltarescuG
      et al.Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.Medicine (Baltimore)200281122-38pmid:11889412
      Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81:122-38. [PMID: 11889412]
      CrossRefMedline
    4. 4.↵
      1. MacDermotKD,
      2. HolmesA,
      3. MinersAH
      Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.J Med Genet200138750-60pmid:11694547
      MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750-60. [PMID: 11694547]
      Abstract/FREE Full Text
    5. 5.↵
      1. ColombiA,
      2. KostyalA,
      3. BracherR,
      4. GloorF,
      5. MazziR,
      6. ThölenH
      Angiokeratoma corporis diffusum—Fabry's disease.Helv Med Acta19673467-83pmid:5592081
      Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Thölen H. Angiokeratoma corporis diffusum—Fabry's disease. Helv Med Acta. 1967;34:67-83. [PMID: 5592081]
      MedlineWeb of Science
    6. 6.↵
      1. MacDermotKD,
      2. HolmesA,
      3. MinersAH
      Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females [Letter].J Med Genet200138769-75pmid:11732485
      MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females [Letter]. J Med Genet. 2001;38:769-75. [PMID: 11732485]
      FREE Full Text
    7. 7.↵
      1. TsakirisD,
      2. SimpsonHK,
      3. JonesEH,
      4. BriggsJD,
      5. ElinderCG,
      6. MendelS
      et al.Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.Nephrol Dial Transplant199611Suppl 74-20pmid:9067983
      Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant. 1996;11 Suppl 7:4-20. [PMID: 9067983]
      Abstract/FREE Full Text
    8. 8.↵
      1. ThadhaniR,
      2. WolfM,
      3. WestML,
      4. TonelliM,
      5. RuthazerR,
      6. PastoresGM
      et al.Patients with Fabry disease on dialysis in the United States.Kidney Int200261249-55pmid:11786107
      Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int. 2002;61:249-55. [PMID: 11786107]
      CrossRefMedlineWeb of Science
    9. 9.↵
      1. von ScheidtW,
      2. EngCM,
      3. FitzmauriceTF,
      4. ErdmannE,
      5. HübnerG,
      6. OlsenEG
      et al.An atypical variant of Fabry's disease with manifestations confined to the myocardium.N Engl J Med1991324395-9pmid:1846223
      von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hübner G, Olsen EG, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991;324:395-9. [PMID: 1846223]
      MedlineWeb of Science
    10. 10.↵
      1. NakaoS,
      2. TakenakaT,
      3. MaedaM,
      4. KodamaC,
      5. TanakaA,
      6. TaharaM
      et al.An atypical variant of Fabry's disease in men with left ventricular hypertrophy.N Engl J Med1995333288-93pmid:7596372
      Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288-93. [PMID: 7596372]
      Abstract/FREE Full Text
    11. 11.↵
      1. NakaoS,
      2. KodamaC,
      3. TakenakaT,
      4. TanakaA,
      5. YasumotoY,
      6. YoshidaA
      et al.Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype.Kidney Int200364801-7pmid:12911529
      Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003;64:801-7. [PMID: 12911529]
      CrossRefMedlineWeb of Science
    12. 12.↵
      1. EngCM,
      2. BanikazemiM,
      3. GordonRE,
      4. GoldmanM,
      5. PhelpsR,
      6. KimL
      et al.A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.Am J Hum Genet200168711-22pmid:11179018
      Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68:711-22. [PMID: 11179018]
      CrossRefMedlineWeb of Science
    13. 13.↵
      1. EngCM,
      2. GuffonN,
      3. WilcoxWR,
      4. GermainDP,
      5. LeeP,
      6. WaldekS
      et al.Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease.N Engl J Med20013459-16pmid:11439963
      Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. N Engl J Med. 2001;345:9-16. [PMID: 11439963]
      Abstract/FREE Full Text
    14. 14.↵
      1. ThurbergBL,
      2. RennkeH,
      3. ColvinRB,
      4. DikmanS,
      5. GordonRE,
      6. CollinsAB
      et al.Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.Kidney Int2002621933-46pmid:12427118
      Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62:1933-46. [PMID: 12427118]
      CrossRefMedlineWeb of Science
    15. 15.↵
      1. WilcoxWR,
      2. BanikazemiM,
      3. GuffonN,
      4. WaldekS,
      5. LeeP,
      6. LinthorstGE
      et al.Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.Am J Hum Genet20047565-74pmid:15154115
      Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet. 2004;75:65-74. [PMID: 15154115]
      CrossRefMedlineWeb of Science
    16. 16.↵
      1. ThurbergBL,
      2. Randolph ByersH,
      3. GranterSR,
      4. PhelpsRG,
      5. GordonRE,
      6. O'CallaghanM
      Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies.J Invest Dermatol2004122900-8pmid:15102080
      Thurberg BL, Randolph Byers H, Granter SR, Phelps RG, Gordon RE, O'Callaghan M. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol. 2004;122:900-8. [PMID: 15102080]
      CrossRefMedlineWeb of Science
    17. 17.↵
      1. StevensLA,
      2. CoreshJ,
      3. GreeneT,
      4. LeveyAS
      Assessing kidney function—measured and estimated glomerular filtration rate.N Engl J Med20063542473-83pmid:16760447
      Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-83. [PMID: 16760447]
      FREE Full Text
    18. 18.↵
      1. BraunwaldE,
      2. AntmanEM,
      3. BeasleyJW,
      4. CaliffRM,
      5. CheitlinMD,
      6. HochmanJS
      et al.ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).J Am Coll Cardiol200036970-1062pmid:10987629
      Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062. [PMID: 10987629]
      FREE Full Text
    19. 19.↵
      1. O'BrienPC,
      2. FlemingTR
      A multiple testing procedure for clinical trials.Biometrics197935549-56pmid:497341
      O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-56. [PMID: 497341]
      CrossRefMedlineWeb of Science
    20. 20.↵
      Schiffmann R, Kopp JB, Austin H, Moore DF, Sabnis S, Weibel T, et al. Efficacy and safety of enzyme replacement therapy for Fabry disease demonstrated by a double-blind placebo-controlled trial [Abstract]. Presented at the American Society of Human Genetics Annual Meeting, Philadelphia, Pennsylvania, 3-7 October 2000:Abstract 135.
    21. 21.↵
      1. GouldAL,
      2. ShihWJ
      Modifying the design of ongoing trials without unblinding.Stat Med19981789-100pmid:9463852
      Gould AL, Shih WJ. Modifying the design of ongoing trials without unblinding. Stat Med. 1998;17:89-100. [PMID: 9463852]
      CrossRefMedlineWeb of Science
    22. 22.↵
      1. KalbfleischJD,
      2. PrenticeRL
      Relative risk (Cox) regression models.The Statistical Analysis of Failure Time Data. 2nd ed.Hoboken, NJJ Wiley200295-147
      Kalbfleisch JD, Prentice RL. Relative risk (Cox) regression models. In: The Statistical Analysis of Failure Time Data. 2nd ed. Hoboken, NJ: J Wiley; 2002:95-147.
    23. 23.↵
      1. HosmerDW,
      2. LemenshowS
      Interpretation of a fitted proportional hazards regression model.Applied Survival Analysis: Regression Modeling of Time to Event Data.Hoboken, NJJ Wiley1999137-52
      Hosmer DW, Lemenshow S. Interpretation of a fitted proportional hazards regression model. In: Applied Survival Analysis: Regression Modeling of Time to Event Data. Hoboken, NJ: J Wiley; 1999:137-52.
    24. 24.↵
      1. RothmanKJ,
      2. GreenlandS
      Modern Epidemiology. 2nd ed.PhiladelphiaLippincott-Raven1998256-8
      Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998:256-8.
    25. 25.↵
      1. FisherLD,
      2. van BelleG
      Biostatistics: A Methodology for the Health Sciences.Hoboken, NJJ Wiley1993
      Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences. Hoboken, NJ: J Wiley; 1993.
    26. 26.↵
      1. FleissJL,
      2. LevinB,
      3. PaikMC
      Comparative studies: cross-sectional, naturalistic, or multinomial sampling.Statistical Methods for Rates and Proportions. 3rd ed.Hoboken, NJJ Wiley2003
      Fleiss JL, Levin B, Paik MC. Comparative studies: cross-sectional, naturalistic, or multinomial sampling. In: Statistical Methods for Rates and Proportions. 3rd ed. Hoboken, NJ: J Wiley; 2003.
    27. 27.↵
      World Health Organization Adverse Reaction Terminology (WHO-ART). Uppsala, Sweden: World Health Organization Collaborating Centre for International Drug Monitoring, Uppsala Monotoring Centre; 1993. Available at http://www.umc-products.com/DynPage.aspx?id=4918&mn=1107. Accessed on 15 November 2006.
    28. 28.↵
      U.S. Food and Drug Administration Center for Drug Evaluation and Research. Endocrinologic and Metabolic Advisory Committee. Transcript of 13 January 2003 Meeting. Accessed at http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3917T1.pdf on 10 October 2006.
    29. 29.↵
      1. De SchoenmakereG,
      2. ChauveauD,
      3. GrünfeldJP
      Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function.Nephrol Dial Transplant20031833-5pmid:12480957
      De Schoenmakere G, Chauveau D, Grünfeld JP. Enzyme replacement therapy in Anderson-Fabry's disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant. 2003;18:33-5. [PMID: 12480957]
      Abstract/FREE Full Text
    30. 30.↵
      1. WaldekS
      PR interval and the response to enzyme-replacement therapy for Fabry's disease [Letter].N Engl J Med20033481186-7pmid:12646684
      Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry's disease [Letter]. N Engl J Med. 2003;348:1186-7. [PMID: 12646684]
      FREE Full Text
    31. 31.↵
      1. WeidemannF,
      2. BreunigF,
      3. BeerM,
      4. SandstedeJ,
      5. TurschnerO,
      6. VoelkerW
      et al.Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.Circulation20031081299-301pmid:12952834
      Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003;108:1299-301. [PMID: 12952834]
      Abstract/FREE Full Text
    32. 32.↵
      1. HilzMJ,
      2. BrysM,
      3. MartholH,
      4. StemperB,
      5. DütschM
      Enzyme replacement therapy improves function of C-, A[dgr ]-, and A[Bgr ]-nerve fibers in Fabry neuropathy.Neurology2004621066-72pmid:15079003
      Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M. Enzyme replacement therapy improves function of C-, A[dgr ]-, and A[Bgr ]-nerve fibers in Fabry neuropathy. Neurology. 2004;62:1066-72. [PMID: 15079003]
      Abstract/FREE Full Text
    33. 33.↵
      1. GuffonN,
      2. FouilhouxA
      Clinical benefit in Fabry patients given enzyme replacement therapy—a case series.J Inherit Metab Dis200427221-7pmid:15159653
      Guffon N, Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy—a case series. J Inherit Metab Dis. 2004;27:221-7. [PMID: 15159653]
      CrossRefMedlineWeb of Science
    34. 34.↵
      1. MignaniR,
      2. PanichiV,
      3. GiudicissiA,
      4. TaccolaD,
      5. BoscaroF,
      6. FelettiC
      et al.Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.Kidney Int2004651381-5pmid:15086478
      Mignani R, Panichi V, Giudicissi A, Taccola D, Boscaro F, Feletti C, et al. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Kidney Int. 2004;65:1381-5. [PMID: 15086478]
      CrossRefMedlineWeb of Science
    35. 35.↵
      1. SpinelliL,
      2. PisaniA,
      3. SabbatiniM,
      4. PetrettaM,
      5. AndreucciMV,
      6. ProcacciniD
      et al.Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.Clin Genet200466158-65pmid:15253767
      Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet. 2004;66:158-65. [PMID: 15253767]
      CrossRefMedlineWeb of Science
    36. 36.↵
      1. BanikazemiM,
      2. UllmanT,
      3. DesnickRJ
      Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.Mol Genet Metab200585255-9pmid:15939645
      Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab. 2005;85:255-9. [PMID: 15939645]
      Medline
    37. 37.↵
      1. PisaniA,
      2. SpinelliL,
      3. SabbatiniM,
      4. AndreucciMV,
      5. ProcacciniD,
      6. AbbaterussoC
      et al.Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.Am J Kidney Dis200546120-7pmid:15983965
      Pisani A, Spinelli L, Sabbatini M, Andreucci MV, Procaccini D, Abbaterusso C, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis. 2005;46:120-7. [PMID: 15983965]
      CrossRefMedlineWeb of Science
    38. 38.↵
      1. BreunigF,
      2. WeidemannF,
      3. StrotmannJ,
      4. KnollA,
      5. WannerC
      Clinical benefit of enzyme replacement therapy in Fabry disease.Kidney Int2006691216-21pmid:16609685
      Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69:1216-21. [PMID: 16609685]
      CrossRefMedlineWeb of Science
    39. 39.↵
      1. EllederM,
      2. PoupetováH,
      3. KožichV
      [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I].Cesk Patol1998347-12pmid:9560877
      Elleder M, Poupetová H, Kožich V. [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]. Cesk Patol. 1998;34:7-12. [PMID: 9560877]
      Medline
    40. 40.↵
      1. WeinrebNJ,
      2. CharrowJ,
      3. AnderssonHC,
      4. KaplanP,
      5. KolodnyEH,
      6. MistryP
      et al.Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.Am J Med2002113112-9pmid:12133749
      Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113:112-9. [PMID: 12133749]
      CrossRefMedlineWeb of Science
    41. 41.↵
      1. SeguraJ,
      2. CampoC,
      3. RuilopeLM
      Proteinuria: an underappreciated risk factor in cardiovascular disease.Curr Cardiol Rep20024458-62pmid:12379163
      Segura J, Campo C, Ruilope LM. Proteinuria: an underappreciated risk factor in cardiovascular disease. Curr Cardiol Rep. 2002;4:458-62. [PMID: 12379163]
      Medline
    42. 42.↵
      1. SeguraJ,
      2. CampoC,
      3. RuilopeLM
      Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension.Kidney Int Suppl2004S45-9pmid:15485417
      Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int Suppl. 2004:S45-9. [PMID: 15485417]
      Medline
    43. 43.↵
      1. ShahinfarS,
      2. DicksonT,
      3. ZhangZ,
      4. KeaneWF,
      5. BrennerBM
      Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study.Kidney Int Suppl2005S48-51pmid:15663528
      Shahinfar S, Dickson T, Zhang Z, Keane WF, Brenner BM. Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL Study. Kidney Int Suppl. 2005:S48-51. [PMID: 15663528]
      Medline
    44. 44.↵
      1. GrimmRH, Jr,
      2. SvendsenKH,
      3. KasiskeB,
      4. KeaneWF,
      5. WahiMM
      Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial.Kidney Int Suppl199763S10-4pmid:9407412
      Grimm RH Jr, Svendsen KH, Kasiske B, Keane WF, Wahi MM. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl. 1997;63:S10-4. [PMID: 9407412]
      CrossRefMedline
    45. 45.↵
      1. de ZeeuwD,
      2. RemuzziG,
      3. ParvingHH,
      4. KeaneWF,
      5. ZhangZ,
      6. ShahinfarS
      et al.Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.Kidney Int2004652309-20pmid:15149345
      de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309-20. [PMID: 15149345]
      CrossRefMedlineWeb of Science
    46. 46.↵
      1. de ZeeuwD,
      2. RemuzziG,
      3. ParvingHH,
      4. KeaneWF,
      5. ZhangZ,
      6. ShahinfarS
      et al.Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.Circulation2004110921-7pmid:15302780
      de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-7. [PMID: 15302780]
      Abstract/FREE Full Text
    47. 47.↵
      European Medicines Agency Committee for Medicinal Products for Human Use. Guidelines on clinical trials in small populations. London: European Medicines Agency; 2006. Accessed at http://www.emea.eu.int/pdfs/human/ewp/8356105en.pdf on 2 October 2006.
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med January 16, 2007 vol. 146 no. 2 77-86
    1. AbstractFREE
    2. Figures
    3. » Full Text
    4. Full Text (PDF)
    5. Trial Portal

    Rapid Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues